131 related articles for article (PubMed ID: 37402350)
1. Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase.
Pelizzari G; Bertoli E; Buriolla S; Vitale MG; Basile D; Palmero L; Zara D; Iacono D; Andrea F; Pascoletti G; Bolzonello S; Garutti M; Fasola G; Puglisi F; Minisini AM
Melanoma Res; 2023 Oct; 33(5):398-405. PubMed ID: 37402350
[TBL] [Abstract][Full Text] [Related]
2. Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
Bander ED; Yuan M; Carnevale JA; Reiner AS; Panageas KS; Postow MA; Tabar V; Moss NS
Cancer; 2021 Jun; 127(12):2062-2073. PubMed ID: 33651913
[TBL] [Abstract][Full Text] [Related]
3. Real-world analysis of clinicopathological characteristics, survival rates, and prognostic factors in patients with melanoma brain metastases in China.
Wang Y; Lian B; Si L; Chi Z; Sheng X; Wang X; Mao L; Tang B; Li S; Yan X; Bai X; Zhou L; Cui C; Guo J
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2731-2740. PubMed ID: 33611636
[TBL] [Abstract][Full Text] [Related]
4. Are prognostic indices for brain metastases of melanoma still valid in the stereotactic era?
Badakhshi H; Engeling F; Budach V; Ghadjar P; Zschaeck S; Kaul D
Radiat Oncol; 2018 Jan; 13(1):3. PubMed ID: 29316943
[TBL] [Abstract][Full Text] [Related]
5. Combined immunotherapy with nivolumab and ipilimumab with and without local therapy in patients with melanoma brain metastasis: a DeCOG* study in 380 patients.
Amaral T; Kiecker F; Schaefer S; Stege H; Kaehler K; Terheyden P; Gesierich A; Gutzmer R; Haferkamp S; Uttikal J; Berking C; Rafei-Shamsabadi D; Reinhardt L; Meier F; Karoglan A; Posch C; Gambichler T; Pfoehler C; Thoms K; Tietze J; Debus D; Herbst R; Emmert S; Loquai C; Hassel JC; Meiss F; Tueting T; Heinrich V; Eigentler T; Garbe C; Zimmer L;
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32221017
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.
Ahmed KA; Abuodeh YA; Echevarria MI; Arrington JA; Stallworth DG; Hogue C; Naghavi AO; Kim S; Kim Y; Patel BG; Sarangkasiri S; Johnstone PA; Sahebjam S; Khushalani NI; Forsyth PA; Harrison LB; Yu M; Etame AB; Caudell JJ
Ann Oncol; 2016 Dec; 27(12):2288-2294. PubMed ID: 27637745
[TBL] [Abstract][Full Text] [Related]
7. Novel risk scores for survival and intracranial failure in patients treated with radiosurgery alone to melanoma brain metastases.
Chowdhury IH; Ojerholm E; McMillan MT; Miller D; Kolker JD; Kurtz G; Dorsey JF; Nagda SN; Geiger GA; Brem S; O'Rourke DM; Zager EL; Gangadhar T; Schuchter L; Lee JY; Alonso-Basanta M
Radiat Oncol; 2015 Dec; 10():248. PubMed ID: 26626714
[TBL] [Abstract][Full Text] [Related]
8. Validation of the Chowdhury overall survival score in patients with melanoma brain metastasis treated with Gamma Knife Radiosurgery.
Rodenburg RJ; Hanssens PE; Ho VKY; Beerepoot LV
J Neurooncol; 2018 Jun; 138(2):391-399. PubMed ID: 29470692
[TBL] [Abstract][Full Text] [Related]
9. Comparison of prognostic indices in patients who undergo melanoma brain metastasis radiosurgery.
Kano H; Morales-Restrepo A; Iyer A; Weiner GM; Mousavi SH; Kirkwood JM; Tarhini AA; Flickinger JC; Lunsford LD
J Neurosurg; 2018 Jan; 128(1):14-22. PubMed ID: 28106495
[TBL] [Abstract][Full Text] [Related]
10. Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study.
Gatterbauer B; Hirschmann D; Eberherr N; Untersteiner H; Cho A; Shaltout A; Göbl P; Fitschek F; Dorfer C; Wolfsberger S; Kasprian G; Höller C; Frischer JM
Cancer Med; 2020 Jun; 9(11):4026-4036. PubMed ID: 32249551
[TBL] [Abstract][Full Text] [Related]
11. Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG.
Franklin C; Mohr P; Bluhm L; Grimmelmann I; Gutzmer R; Meier F; Garzarolli M; Weichenthal M; Pfoehler C; Herbst R; Terheyden P; Utikal J; Ulrich J; Debus D; Haferkamp S; Kaatz M; Forschner A; Leiter U; Nashan D; Kreuter A; Sachse M; Welzel J; Heinzerling L; Meiss F; Weishaupt C; Gambichler T; Weyandt G; Dippel E; Schatton K; Celik E; Trommer M; Helfrich I; Roesch A; Zimmer L; Livingstone E; Schadendorf D; Horn S; Ugurel S
J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35688555
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors for overall survival after radiosurgery for brain metastases from melanoma.
Marcus DM; Lowe M; Khan MK; Lawson DH; Crocker IR; Shelton JW; Melton A; Maynard N; Delman KA; Carlson GW; Rizzo M
Am J Clin Oncol; 2014 Dec; 37(6):580-4. PubMed ID: 23428955
[TBL] [Abstract][Full Text] [Related]
13. Determinants of survival in patients with brain metastases from cutaneous melanoma.
Staudt M; Lasithiotakis K; Leiter U; Meier F; Eigentler T; Bamberg M; Tatagiba M; Brossart P; Garbe C
Br J Cancer; 2010 Apr; 102(8):1213-8. PubMed ID: 20372154
[TBL] [Abstract][Full Text] [Related]
14. Melanoma brain metastasis: the impact of stereotactic radiosurgery, BRAF mutational status, and targeted and/or immune-based therapies on treatment outcome.
Kotecha R; Miller JA; Venur VA; Mohammadi AM; Chao ST; Suh JH; Barnett GH; Murphy ES; Funchain P; Yu JS; Vogelbaum MA; Angelov L; Ahluwalia MS
J Neurosurg; 2018 Jul; 129(1):50-59. PubMed ID: 28799876
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and grading systems for overall survival in patients treated with radiosurgery for brain metastases: variation by primary site.
Golden DW; Lamborn KR; McDermott MW; Kunwar S; Wara WM; Nakamura JL; Sneed PK
J Neurosurg; 2008 Dec; 109 Suppl():77-86. PubMed ID: 19123892
[TBL] [Abstract][Full Text] [Related]
16. Real-world data on melanoma brain metastases and survival outcome.
Pedersen S; Møller S; Donia M; Persson GF; Svane IM; Ellebaek E
Melanoma Res; 2022 Jun; 32(3):173-182. PubMed ID: 35256571
[TBL] [Abstract][Full Text] [Related]
17. Early imaging radioresponsiveness of melanoma brain metastases as a predictor of patient prognosis.
Zubatkina I; Ivanov P
J Neurosurg; 2018 Aug; 129(2):354-365. PubMed ID: 28841116
[TBL] [Abstract][Full Text] [Related]
18. Prognostic models predicting survival of patients with brain metastases: integration of lactate dehydrogenase, albumin and extracranial organ involvement.
Nieder C; Marienhagen K; Dalhaug A; Aandahl G; Haukland E; Pawinski A
Clin Oncol (R Coll Radiol); 2014 Aug; 26(8):447-52. PubMed ID: 24702741
[TBL] [Abstract][Full Text] [Related]
19. Current Treatment of Melanoma Brain Metastasis.
Rishi A; Yu HM
Curr Treat Options Oncol; 2020 Apr; 21(6):45. PubMed ID: 32350685
[TBL] [Abstract][Full Text] [Related]
20. Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma.
Schvartsman G; Ma J; Bassett RL; Haydu LE; Amaria RN; Hwu P; Wong MK; Hwu WJ; Diab A; Patel SP; Davies MA; Hamerschlak N; Tawbi HA; Glitza Oliva IC
Cancer; 2019 Dec; 125(23):4193-4202. PubMed ID: 31398264
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
